Pharmamarketeer

TLC begins patient enrollment in phase III EXCELLENCE trial of TLC599 to treat osteoarthritis knee pain

Osteoarthritis knee pain

TLC, a clinical-stage specialty pharmaceutical company, announced that the first patient has been enrolled in EXCELLENCE, the phase III pivotal clinical trial for TLC599 in patients with osteoarthritis knee pain. TLC599 is a non-opioid, proprietary BioSeizer sustained release formulation of dexamethasone sodium phosphate (DSP) intended to manage OA pain for up to six months.

Voor andere berichten over phase III berichten, KLIK HIER! 

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl